Fifteen per cent of patients had a change in their treatment before falling. The average number of drugs per patient was nine per day. In these patients, the rate of prescription of drugs at risk of falling was high (87% for hypotensive treatments and 91% for inducing drowsiness treatments). A very high consumption of diuretics (40%) and benzodiazepines (60%) was observed. The combination of benzodiazepines was found in 16% of patients. Respectively, 24% and 65% of patients had a modification in their hypotensive and inducing drowsiness treatments.

Conclusion The use of drugs that increased the risk of falling was common in our hospital. The recent change in inducing drowsiness treatments seemed to increase the risk of falling.

Pharmaceutical interventions with prescribers on good prescribing practices in the elderly should be strengthened to minimise the use of drugs at risk of falling.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Thanks to the Health Framework.

No conflict of interest.

5PSQ-127 DISPENSATION OF FINITE MEDICATION AT DISCHARGE IN THE COMPLEX CHRONIC PATIENT

L Gómez-Sayago, L Fito*, MT Criado-Illana. *Complejo Asistencial de Segovia, Servicio de Farmacia, Segovia, Spain*

10.1136/ejhp-pharm-2019-eahpconf.560

Background Within the programmes of continuous care of the complex chronic patient (CCP), there are initiatives to improve adherence and continuity of care. Most frequent is dispensing medication upon discharge.

A discharge finite medication (FM) programme for complex chronic diseases (DMCDP) was implemented in the continuity care unit of internal medicine (UCA) in our hospital.

Purpose Evaluate the DMCDP from our hospital.

Material and methods FM is defined as drugs that the patient doesn't have and whose estimated duration of treatment is less than 30 days.

A prospective observational study was designed with all patients classified as CCP admitted to the UCA during the first 6 months of 2018, to compare cost and number of doses dispensed (DD) between the community pharmacy (CP) system vs the DMCDP programme.

An Excel database was created. Variables: age, sex, medication dispensed, therapeutic group, indication, duration and days until end of treatment, units dispensed and saved vs CP more adjusted to treatment presentation, estimated cost in CP according to Remedios, cost of hospital dispensation and opportunity cost. All data were analysed with XLS Stat for descriptive statistics.

Tools: history of primary care, electronic prescription, medication bag, informative interview on admission and discharge, medication sheet at discharge, hourly chart, FM in unit doses with posology until the end of treatment and in daily kits dated for medications with variable posology such as descending corticoid patterns. Remedios data base.

Results Sixty-six patients were studied. Age 83 (44–98) years.

All patients had at least seven medical prescriptions: 100% of admissions were reconciled and interviewed on admission and discharge.

Thirty-four (47.2%) patients required FM according to discharge medical prescription to finish initiated hospital

treatments for anticoagulation (78%), respiratory infection (ABR) (14%), urinary infection (3%), other infections (4%) and hepatic encephalopathy (1%).

Medication DD avoided were: systemic corticosteroids (59.3%), antibacterial (34.7%) and antithrombotic antihaemorrhagic (4.7%).

Cost savings in medication for the national health system (88.27%). Pathologies' greatest savings were AC (78%) and ABR(14%).

The biggest problem on admission and discharge was lack of time.

Conclusion A discharge medication programme led by a hospital pharmacist, reinforces understanding and compliance for each patient, decreases the risk failure due to lack of adherence, knowledge or accessibility problems. In addition, it promotes rational use, since dispensing of the exact units reduces the possibility of future self-medication at home.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Jago-Byrne MM-C, et al. (GPI) discharge management: safer discharges and improved information. *Int J Clin Pharma* 2011;71:1–10. (<http://statements.eahp.eu/sites/default/files/resources/GPI%204.2-4.3-4.4.pdf>)

No conflict of interest.

5PSQ-128 PHARMACOTHERAPEUTIC PROFILE AND RISK OF DRUG-RELATED PROBLEMS AND DRUG INTERACTIONS IN HIV+ PATIENTS OF A HEALTH AREA

M Onteniente Candela, I Salar Valverde, M Gil Candel*, C Pastor Mondéjar, C Inieta Navalón, C Caballero Requejo, M García Coronel, E Urbieta Sanz. *Hospital Universitario Reina Sofía, Hospital Pharmacy, Murcia, Spain*

10.1136/ejhp-pharm-2019-eahpconf.561

Background The expected lifespan of HIV +patients has increased dramatically as a result of improved antiretroviral therapy (ART), with the consequent increase in comorbidities and polypharmacy.

Purpose To analyse the profile of comorbidities and polypharmacy in HIV +patients of a Health Area and determine their influence on the risk of presenting drug-related problems (DRPs) and potential clinically significant drug interactions (CSDIs).

Material and methods Retrospective observational study conducted in a Reference Hospital Area that treated 457 HIV +patients with ART. We included all HIV +patients who collected ART in our pharmacy service during a randomly chosen week of March 2018. Variables included in the analysis were: demographics (age, sex) and clinical (viral load (VL), comorbidities) from computerised medical records and pharmacotherapeutic (ART scheme, dispensing data and concomitant treatment) from a management programme (Savac) and application AGORA PLUS®. Patients with ≥2 chronic non-AIDS pathologies were considered pluripathologic and polymedicated if they were prescribed ≥5 non-ART drugs. The risk of DRPs was obtained from the PREDICTOR tool of the Spanish Society of Hospital Pharmacy and CSDIs from the Lexicomp database. Statistical analysis was performed using SPSS v23.0.

Results We included 120 patients (76.7% males), with a mean age of 51.15±9.61 years (59.17%>50 years' old). 94.17% had undetectable VL. 54.2% patients were pluripathologic